What should you know about BCG and chemotherapy for bladder cancer?

A thin catheter carries the chosen treatment through the urethra into the bladder. The medicine remains mainly in the bladder for a planned period and is then passed out. Choice and schedule depend on the tumour's pathology, risk category, previous treatment, current health, and whether the bladder is safe to catheterise that day.

BCG contains weakened bacteria that stimulate an immune response within the bladder. Intravesical chemotherapy uses a cancer-killing medicine in the same compartment. Neither should be confused with systemic treatment given into a vein or by mouth, which circulates throughout the body and has a different side-effect pattern.

These bladder treatments are commonly considered after visible tumour has been removed through the urethra. They aim to treat abnormal cells that may remain in the lining and reduce the chance of the disease returning or progressing. Cystoscopy and urine checks may still be needed because treatment response cannot be judged from symptoms alone.

Tell the urology team about fever, urinary infection symptoms, visible blood, trouble passing urine, pregnancy possibility, immune-suppressing conditions, and all medicines. The team may postpone treatment if infection, significant bleeding, or difficult catheter placement could increase harm. Follow the unit's directions about fluids before the visit and safe toilet hygiene afterward.

Keep a note of urinary burning, frequency, bleeding, fever, rash, joint symptoms, or fatigue and report them according to the treatment instructions. Attend planned cystoscopies even if you feel well, and verify whether the next appointment is another instillation, a bladder examination, or a review of tissue results.

Contact the treatment team promptly for fever, chills, worsening urinary pain, heavy bleeding, clots, inability to pass urine, or symptoms that are stronger or last longer than the team said to expect. Seek urgent medical care for breathing difficulty, confusion, fainting, severe weakness, or rapidly worsening illness. After BCG, persistent fever or feeling systemically unwell can indicate infection beyond the bladder and requires immediate clinical advice; tell the clinician that intravesical BCG was given.

Ask whether the proposed medicine is BCG or chemotherapy, why it fits the pathology and risk category, and what would cause a dose to be delayed. Clarify the planned course, urine-handling precautions at home, expected bladder symptoms, and the direct contact route for fever. Also ask how response will be checked and what options may be discussed if the cancer persists or returns.